Making best use of evidence for explicit decisions in health care by Soares, Marta
  
 
Making best use of evidence for explicit 
decisions in health care  
 


















List of Contents 
Volume 2 
Appendices (continued)............................................................................ 418 
Paper 4. .................................................................................................................................. 419 
Paper 5. .................................................................................................................................. .836 
Paper 6. ................................................................................................................................... 855 








Paper 4.  
Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E et al. Tumour 
necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial 
spondyloarthritis: a systematic review and economic evaluation. Health 






































































































































































































































































































































































































































Paper 5.  
Soares MO, Bojke L, Dumville J, Iglesias C, Cullum N, Claxton K. Methods to elicit 
experts’ beliefs over uncertain quantities: application to a cost effectiveness 
transition model of negative pressure wound therapy for severe pressure 




















Paper 6.  
Soares MO; Dumville J; Ashby R; Iglesias C; Bojke L; Adderley U; McGinnis E; 
Stubbs N; Torgerson D; Claxton K; Cullum N. Methods to assess cost 
effectiveness and value of further research when data are sparse: negative 


























1. Palmer S, Raftery J. Economic Notes: opportunity cost. BMJ. 
1999;318(7197):1551-1552. 
2. Claxton K, Martin S, Soares M, et al. Methods for the estimation of the 
National Institute for Health and Care Excellence cost-effectiveness threshold. 
Health Technol Assess. 2015;19(14):1-503, v-vi. 
3. Stinnett AA, Mullahy J. Net health benefits: a new framework for the 
analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(2 
Suppl):S68-80. 
4. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: 
what it is and what that means. Pharmacoeconomics. 2008;26(9):733-744. 
5. National Institute for Health and Care Excellence.  
https://www.nice.org.uk/. Accessed 24.03, 2017. 
6. Canadian Agency for Drugs and Technologies in Health. CADTH.  
https://www.cadth.ca/, 2017. 
7. Pharmaceutical Benefits Advisory Committee.  
https://pbac.pbs.gov.au/home.html. Accessed 24.03, 2017. 
8. Infarmed -- Autoridade Nacional do Medicamento e Produtos de Saúde I.P. 
Infarmed.  http://www.infarmed.pt/. Accessed 24.03, 2017. 
9. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based 
economic evaluation for health care decision making? Health Econ. 2006;15(7):677-
687. 
10. Banta D. The development of health technology assessment. Health Policy. 
2003;63(2):121-132. 
11. Drummond M. Methods for the economic evaluation of health care 
programmes. Fourth edition. ed. Oxford, United Kingdom ; New York, NY, USA: 
Oxford University Press; 2015. 
12. Sutton AJ. Methods for meta-analysis in medical research. Chichester ; New 
York: J. Wiley; 2000. 
13. Caldwell DM, Welton NJ, Ades AE. Mixed treatment comparison analysis 
provides internally coherent treatment effect estimates based on overviews of 
reviews and can reveal inconsistency. J Clin Epidemiol. 2010;63(8):875-882. 
14. Sutton AJ, Higgins JP. Recent developments in meta-analysis. Stat Med. 
2008;27(5):625-650. 
 879 
15. Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence synthesis for decision 
making 1: introduction. Med Decis Making. 2013;33(5):597-606. 
16. Saramago P, Manca A, Sutton AJ. Deriving input parameters for cost-
effectiveness modeling: taxonomy of data types and approaches to their statistical 
synthesis. Value Health. 2012;15(5):639-649. 
17. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic 
evaluation. Oxford: Oxford University Press; 2006. 
18. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for 
decision analytic modeling in health-care evaluation: Report of the ISPOR task force 
on good research practices-modeling studies. Value in Health. 2003;6(1):9-17. 
19. Briggs A, Sculpher M. An introduction to Markov modelling for economic 
evaluation. Pharmacoeconomics. 1998;13(4):397-409. 
20. Briggs A. Probabilistic analysis of cost-effectiveness models: statistical 
representation of parameter uncertainty. Value Health. 2005;8(1):1-2. 
21. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic 
sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis 
Making. 1985;5(2):157-177. 
22. Cooper NJ, Spiegelhalter D, Bujkiewicz S, Dequen P, Sutton AJ. Use of 
implicit and explicit bayesian methods in health technology assessment. Int J 
Technol Assess Health Care. 2013;29(3):336-342. 
23. Bojke L, Claxton K, Sculpher M, Palmer S. Characterizing structural 
uncertainty in decision analytic models: a review and application of methods. Value 
Health. 2009;12(5):739-749. 
24. Mahon R, Manca A, Palmer S. Where Did the Time Go?: Temporal 
Uncertainty in Cost-Effectiveness Decision Models. Value in Health. 
2012;15(7):A373-A373. 
25. Griffin S, Claxton K, Hawkins N, Sculpher M. Probabilistic analysis and 
computationally expensive models: Necessary and required? Value Health. 
2006;9(4):244-252. 
26. Claxton K. The irrelevance of inference: a decision-making approach to the 
stochastic evaluation of health care technologies. J Health Econ. 1999;18(3):341-
364. 
27. Claxton K, Cohen JT, Neumann PJ. When is evidence sufficient? Health 
Affair. 2005;24(1):93-101. 
 880 
28. Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S. A pilot study on the 
use of decision theory and value of information analysis as part of the NHS Health 
Technology Assessment programme. Health Technol Assess. 2004;8(31):1-103, iii. 
29. Ades AE, Lu G, Claxton K. Expected value of sample information calculations 
in medical decision modeling. Medical Decision Making. 2004;24(2):207-227. 
30. Meltzer DO, Hoomans T, Chung JW, Basu A. Minimal modeling approaches 
to value of information analysis for health research. Med Decis Making. 
2011;31(6):E1-E22. 
31. Strong M, Oakley JE, Brennan A. Estimating multiparameter partial 
expected value of perfect information from a probabilistic sensitivity analysis 
sample: a nonparametric regression approach. Med Decis Making. 2014;34(3):311-
326. 
32. Chalkidou K, Hoy A, Littlejohns P. Making a decision to wait for more 
evidence: when the National Institute for Health and Clinical Excellence 
recommends a technology only in the context of research. J R Soc Med. 
2007;100(10):453-460. 
33. Tunis SR, Chalkidou K. Coverage with evidence devlopment: A very good 
beginning, but much to be done. Commentary to Hutton et al. Int J Technol Assess. 
2007;23(4):432-435. 
34. Agency EM. Adaptive pathways.  
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general
_content_000601.jsp. Accessed 24.03, 2017. 
35. Government U. Accelerated access review.  
https://www.gov.uk/government/organisations/accelerated-access-review. 
Accessed 24.03, 2017. 
36. Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A. Balancing 
early market access to new drugs with the need for benefit/risk data: a mounting 
dilemma. Nat Rev Drug Discov. 2008;7(10):818-826. 
37. Department of Health Australian Government. Co-dependent and Hybrid 
Technologies.  http://www.health.gov.au/internet/hta/publishing.nsf/Content/co-
1. Accessed 24.03, 2017. 
38. National Institute for Health and Care Excellence. Diagnostics Assessement 
Programme Manual. 2011. 
39. Meckley LM, Neumann PJ. Personalized medicine: factors influencing 
reimbursement. Health Policy. 2010;94(2):91-100. 
40. NHS England. Cancer Drugs Fund.  
https://www.england.nhs.uk/cancer/cdf/. 
 881 
41. Systemic Anti-Cancer Therapy Dataset.  
http://www.chemodataset.nhs.uk/home. Accessed 24.03, 2017. 
42. National Institute for Health and Care Excellence. Summary of decisions 
2017; https://www.nice.org.uk/about/what-we-do/our-programmes/nice-
guidance/nice-technology-appraisal-guidance/summary-of-decisions. Accessed 10 
February, 2017. 
43. Gregson N, Sparrowhawk K, Mauskopf J, Paul J. Pricing medicines: theory 
and practice, challenges and opportunities. Nat Rev Drug Discov. 2005;4(2):121-
130. 
44. National Institute for Health and Care Excellence. Guide to the methods of 
technology appraisal. London: NICE;2013. 
45. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of 
cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779-787. 
46. Andronis L, Barton P, Bryan S. Sensitivity analysis in economic evaluation: 
an audit of NICE current practice and a review of its use and value in decision-
making. Health Technol Asses. 2009;13(29):1-+. 
47. Hutton J, Trueman P, Henshall C. Coverage with evidence development: An 
examination of conceptual and policy issues. Int J Technol Assess. 2007;23(4):425-
432. 
48. Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ. 
2010;340:c1672. 
49. Griffin SC, Claxton KP, Palmer SJ, Sculpher MJ. Dangerous omissions: the 
consequences of ignoring decision uncertainty. Health Econ. 2011;20(2):212-224. 
50. Palmer S, Smith PC. Incorporating option values into the economic 
evaluation of health care technologies. J Health Econ. 2000;19(5):755-766. 
51. Eckermann S, Willan AR. Expected value of information and decision making 
in HTA. Health Econ. 2007;16(2):195-209. 
52. Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for 
managing uncertainty in decisions on the introduction of new and innovative 
technologies into healthcare systems (vol 28, pg 113, 2010). Pharmacoeconomics. 
2010;28(7):608-608. 
53. Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N. The effect 
of different treatment durations of clopidogrel in patients with non-ST-segment 
elevation acute coronary syndromes: a systematic review and value of information 
analysis. Health Technol Asses. 2009;13(31):1-+. 
 882 
54. Philips Z, Claxton K, Palmer S. The half-life of truth: what are appropriate 
time horizons for research decisions? Med Decis Making. 2008;28(3):287-299. 
55. Higgins JPT, Green S, Cochrane Collaboration. Cochrane handbook for 
systematic reviews of interventions. Chichester, England ; Hoboken, NJ: Wiley-
Blackwell; 2008. 
56. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to 
fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 
2010;1(2):97-111. 
57. DerSimonian R, Kacker R. Random-effects model for meta-analysis of 
clinical trials: an update. Contemp Clin Trials. 2007;28(2):105-114. 
58. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-
effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137-159. 
59. Welton N, Ades AE. Research decisions in the face of heterogeneity: what 
can a new study tell us? Health Econ. 2012;21(10):1196-1200. 
60. Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-
analysis in decision models. Med Decis Making. 2005;25(6):646-654. 
61. Soares MO, Welton NJ, Harrison DA, et al. An evaluation of the feasibility, 
cost and value of information of a multicentre randomised controlled trial of 
intravenous immunoglobulin for sepsis (severe sepsis and septic shock): 
incorporating a systematic review, meta-analysis and value of information analysis. 
Health Technol Assess. 2012;16(7):1-186. 
62. Welton NJ, Soares MO, Palmer S, et al. Accounting for Heterogeneity in 
Relative Treatment Effects for Use in Cost-Effectiveness Models and Value-of-
Information Analyses. Med Decis Making. 2015;35(5):608-621. 
63. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. 
Stat Med. 2002;21(11):1539-1558. 
64. Shuster JJ, Jones LS, Salmon DA. Fixed vs random effects meta-analysis in 
rare event studies: the rosiglitazone link with myocardial infarction and cardiac 
death. Stat Med. 2007;26(24):4375-4385. 
65. Lu G, Ades AE. Combination of direct and indirect evidence in mixed 
treatment comparisons. Stat Med. 2004;23(20):3105-3124. 
66. Nam IS, Mengersen K, Garthwaite P. Multivariate meta-analysis. Stat Med. 
2003;22(14):2309-2333. 
67. Jackson D, Riley R, White IR. Multivariate meta-analysis: potential and 
promise. Stat Med. 2011;30(20):2481-2498. 
 883 
68. Davis S, Tappenden P, Cantrell A. A review of studies examining the 
relationship between progression-free survival and overall survival in advanced or 
metastatic cancer. Sheffield;2012. 
69. Owen RK, Tincello DG, Keith RA. Network meta-analysis: development of a 
three-level hierarchical modeling approach incorporating dose-related constraints. 
Value Health. 2015;18(1):116-126. 
70. Dakin HA, Welton NJ, Ades AE, Collins S, Orme M, Kelly S. Mixed treatment 
comparison of repeated measurements of a continuous endpoint: an example using 
topical treatments for primary open-angle glaucoma and ocular hypertension. Stat 
Med. 2011;30(20):2511-2535. 
71. Warren FC, Abrams KR, Sutton AJ. Hierarchical network meta-analysis 
models to address sparsity of events and differing treatment classifications with 
regard to adverse outcomes. Stat Med. 2014;33(14):2449-2466. 
72. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence 
synthesis in cost-effectiveness analysis. Pharmacoeconomics. 2006;24(1):1-19. 
73. Ades AE, Cliffe S. Markov chain Monte Carlo estimation of a multiparameter 
decision model: consistency of evidence and the accurate assessment of 
uncertainty. Med Decis Making. 2002;22(4):359-371. 
74. Ades AE, Welton NJ, Caldwell D, Price M, Goubar A, Lu G. Multiparameter 
evidence synthesis in epidemiology and medical decision-making. J Health Serv Res 
Policy. 2008;13 Suppl 3:12-22. 
75. Welton NJ. Evidence synthesis for decision making in healthcare. 
Chichester, West Sussex: John Wiley & Sons; 2012. 
76. Jackson D, White IR, Price M, Copas J, Riley RD. Borrowing of strength and 
study weights in multivariate and network meta-analysis. Stat Methods Med Res. 
2015. 
77. Achana FA, Cooper NJ, Bujkiewicz S, et al. Network meta-analysis of 
multiple outcome measures accounting for borrowing of information across 
outcomes. BMC Med Res Methodol. 2014;14:92. 
78. Garthwaite PH, Kadane JB, O'Hagan A. Statistical methods for eliciting 
probability distributions. J Am Stat Assoc. 2005;100(470):680-700. 
79. Montibeller G, von Winterfeldt D. Cognitive and Motivational Biases in 
Decision and Risk Analysis. Risk Anal. 2015;35(7):1230-1251. 
80. O'Hagan A. Uncertain judgements : eliciting experts' probabilities. London ; 
Hoboken, NJ: John Wiley & Sons; 2006. 
 884 
81. Grigore B, Peters J, Hyde C, Stein K. Methods to elicit probability 
distributions from experts: a systematic review of reported practice in health 
technology assessment. Pharmacoeconomics. 2013;31(11):991-1003. 
82. Babuscia A, Cheung KM. An approach to perform expert elicitation for 
engineering design risk analysis: methodology and experimental results. J R Stat Soc 
a Stat. 2014;177(2):475-497. 
83. Bojke L, Claxton K, Bravo-Vergel Y, Sculpher M, Palmer S, Abrams K. Eliciting 
distributions to populate decision analytic models. Value Health. 2010;13(5):557-
564. 
84. Garthwaite PH, Chilcott JB, Jenkinson DJ, Tappenden P. Use of expert 
knowledge in evaluating costs and benefits of alternative service provisions: a case 
study. Int J Technol Assess Health Care. 2008;24(3):350-357. 
85. Vannoortwijk JM, Dekker R, Cooke RM, Mazzuchi TA. Expert Judgment in 
Maintenance Optimization. Ieee T Reliab. 1992;41(3):427-432. 
86. Chaloner K, Rhame FS. Quantifying and documenting prior beliefs in clinical 
trials. Stat Med. 2001;20(4):581-600. 
87. French S. Aggregating expert judgement. Racsam Rev R Acad A. 
2011;105(1):181-206. 
88. Cooke RM. Experts in uncertainty : opinion and subjective probability in 
science. New York: Oxford University Press; 1991. 
89. Bolger F, Rowe G. The aggregation of expert judgment: do good things 
come to those who weight? Risk Anal. 2015;35(1):5-11. 
90. Clemen RT, Winkler RL. Combining probability distributions from experts in 
risk analysis. Risk Analysis. 1999;19(2):187-203. 
91. Stone M. Opinion Pool. Ann Math Stat. 1961;32:1339-&. 
92. Annemans L, Geneste B, Jolain B. Early modelling for assessing health and 
economic outcomes of drug therapy. Value Health. 2000;3(6):427-434. 
93. Garrison LP, Jr., Towse A, Briggs A, et al. Performance-based risk-sharing 
arrangements-good practices for design, implementation, and evaluation: report of 
the ISPOR good practices for performance-based risk-sharing arrangements task 
force. Value Health. 2013;16(5):703-719. 
94. Welton NJ, Thom HH. Value of Information: We've Got Speed, What More 
Do We Need? Med Decis Making. 2015;35(5):564-566. 
95. Claxton K, Griffin S, Koffijberg H, McKenna C. How to estimate the health 
benefits of additional research and changing clinical practice. BMJ. 2015;351:h5987. 
 885 
96. Hettle R, Corbett M, Hinde S, et al. The assessment and appraisal of 
regenerative medicines and cell therapy products: an exploration of methods for 
review, economic evaluation and appraisal. Health Technol Assess. 2017;21(7):1-
204. 
 
